Deep dive into business development in biotech with James Lee

Business development is an essential process for biotech
companies to build relationships with partners and create value
from the deal structures that are based on science. We are taking
a deep dive with James Lee into the mechanics and the framework
that James uses for business development. 


James founded Bridge Biotherapeutics Inc. in 2015 and he
currently serves as the CEO. Bridge has been recognized with the
continuous advancement of clinical-stage programs focused on
pulmonary fibrosis, lung cancer, and immunology. In 2019, James
successfully orchestrated the licensing-out deal with Boehringer
Ingelheim, which marked as one of the largest global deals on a
single compound in Korea.